Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Director departure
|
|
TENAX THERAPEUTICS, INC. (TENX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/15/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 07/19/2023 |
8-K
| Quarterly results |
| 05/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Warrant Agency Agreement, by and between Tenax Therapeutics, Inc. and Direct Transfer LLC",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Form of Common Stock Purchase Warrant",
"Placement Agency Agreement, by and between Tenax Therapeutics, Inc. and Roth Capital Partners, LLC",
"Form of Securities Purchase Agreement by and between Tenax Therapeutics, Inc. and the purchasers named therein",
"Form of Leak-Out Agreement by and between Tenax Therapeutics, Inc. and the persons named therein",
"Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering CHAPEL HILL, NC, February 03, 2023 — Tenax Therapeutics, Inc. , a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the pricing of a public offering of 8,666,666 shares of its common stock and warrants to purchase up to 17,333,332 shares of its common stock at a purchase price of $1.80 per share and associated Public Warrant. The Public Warrants will have an exercise price of $2.25 per share, are immediately exercisable, and will expire five years after their initial exercise date. The offering is expected to close on or about February 7, 2023, subject to customary ..." |
|
| 02/01/2023 |
8-K
| Quarterly results |
| 01/20/2023 |
8-K
| Other Events Interactive Data |
| 01/04/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 10/11/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction MORRISVILLE, N.C. October 10, 2022 – Tenax Therapeutics, Inc. , a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announces the presentation of positive data from a study of PH-HFpEF patients being treated with oral levosimendan. The data, collected during the transition from intravenous to oral levosimendan in the open-label extension of the HELP trial, were presented at the Heart Failure Society of America Scientific Sessions 2022, held from October 1 –3, 2022. Title: “The Transition..." |
|
| 09/20/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/15/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/18/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/20/2022 |
8-K
| Quarterly results |
| 03/24/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/18/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/31/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors Morrisville, NC – January 31, 2022 -- Tenax Therapeutics, Inc. , a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022. Ms. Hunter is an independent director and will chair the Board’s audit and compliance committee. “We are very pleased to welcome Robyn to our Board of Directors”, said Christopher T. Giordano, President and Chief Executive Officer of Tenax Therapeutics. “Robyn brings a wealth of financial and operational expertise within the life sciences industry to our Board. She h..." |
|
| 01/28/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/24/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/05/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/14/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/14/2021 |
8-K
| Quarterly results |
| 07/08/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office... |
| 06/11/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
8-K
| Quarterly results |
| 04/07/2021 |
8-K
| Quarterly results |
| 03/30/2021 |
8-K/A
| Quarterly results |
| 03/02/2021 |
8-K
| Quarterly results |
|
|
|